Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 11/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21652707 | 0.85 | ADH5 (0.63) | ADH5CYP3A4BAZ2BALDH1A1CYP4Z1 | |
| SCHEMBL28424338 | 0.85 | ADH5 (0.63) | ADH5CYP3A4BAZ2BALDH1A1CYP4Z1 | |
| Hydrochloric Acid SCHEMBL29093460 | 0.83 | ADH5 (0.61) | ADH5CYP3A4BAZ2BCYP4Z1HTT | |
| SCHEMBL18290496 | 0.83 | CYP3A4 (0.47) | ADH5CYP3A4ALDH1A1 | |
| SCHEMBL1882019 | 0.83 | CYP3A4 (0.47) | ADH5CYP3A4ALDH1A1 | |
| SCHEMBL31133441 | 0.82 | CES2 (0.43) | ALDH1A1 | |
| SCHEMBL31133445 | 0.82 | CES2 (0.43) | ALDH1A1 | |
| SCHEMBL21818300 | 0.82 | CES2 (0.43) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL17583800 | 0.81 | CYP3A4 (0.46) | ADH5CYP3A4ALDH1A1 | |
| SCHEMBL5223331 | 0.81 | ADH5 (0.55) | ADH5CYP3A4BAZ2BALDH1A1CYP4Z1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655669-B2 | Pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| CN-100404528-C | Novel pyrimidinamine derivatives and use thereof | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | disclosed |
| EP-1546127-B1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| CN-1684951-A | Novel pyrimidinamine derivatives and use thereof | NOVARTIS AG (CH) | 2005-10-19 | — | — | CN | disclosed |
| EP-1546127-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029038-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | TYMP, NME2, DPYD | ADH5 3356/4885CYP3A4 3088/4885BAZ2B 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.